WEKO3
アイテム
{"_buckets": {"deposit": "c8803734-2939-40ed-a221-8658d6601cb6"}, "_deposit": {"created_by": 2, "id": "22664", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "22664"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00022664", "sets": ["1619"]}, "author_link": ["96503"], "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2007-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "43", "bibliographicPageStart": "39", "bibliographicVolumeNumber": "52", "bibliographic_titles": [{"bibliographic_title": "Acta medica Nagasakiensia"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Renal cell carcinoma (RCC) is a common urological malignancy. Patients with low stage RCC have a good prognosis by radical operation. On the other hand, advanced RCC do not respond to most treatment and survival is poor in such patients. Some immuno-therapies were performed to patients with advanced RCC, but the patients who obtained clinically meaningful benefit were very limited. To identify promising targets for novel therapeutic agents, numerous investigations have been carried out regarding the molecular mechanisms of tumor growth and progression. Recently, some molecular-targeting therapies, including anti-vascular endothelial growth factor agent, have demonstrated to prolong survival in phase II and III trials. However, such treatments also showed limited anti-tumoral effects and various severe side effects beyond expectation. These results necessitate more extensive and profound knowledge of pathological features to discuss the treatment strategies for RCC. We have been investigating the molecular mechanism of cancer cell invasion and metastasis in patients with RCC for last few years, and we have obtained several new findings and information about them. In this article, we will describe clinical and pathological significance of several invasion-related and/or angiogenesis-related factors, such as matrix metalloproteinases, thrombospondin, and hepatocyte growth factor/c-Met. These factors are well known to regulate invasive function, angiogenesis, and cancer cell proliferation in various malignant tumors, and animal experiments demonstrated that some selective molecular inhibitors of them could inhibit tumorigenicity and tumor development. Our studies show that some molecular inhibitors may provide a novel therapeutic approach to RCC.", "subitem_description_type": "Abstract"}]}, "item_3_description_64": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Acta medica Nagasakiensia. 2007, 52(2), p.39-43", "subitem_description_type": "Other"}]}, "item_3_relation_42": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/52.39"}]}]}, "item_3_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508430", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00016055", "subitem_source_identifier_type": "ISSN"}]}, "item_3_text_62": {"attribute_name": "sortkey", "attribute_value_mlt": [{"subitem_text_value": "P00039-P00043"}]}, "item_3_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Miyata, Yasuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "96503", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "acta52_02_39.pdf", "filesize": [{"value": "505.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 505400.0, "url": {"label": "acta52_02_39.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/22664/files/acta52_02_39.pdf"}, "version_id": "91556595-fc2a-46f1-b273-bf81c82d7f3e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Moleculartargettherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Thrombospondin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Matrixmetalloproteinases", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Hepatocytegrowthfactorreceptor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Renalcellcarcinoma", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Molecular Targeting Therapy for Renal Cell Carcinoma: Current Status and Our Suggestion", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Molecular Targeting Therapy for Renal Cell Carcinoma: Current Status and Our Suggestion"}]}, "item_type_id": "3", "owner": "2", "path": ["1619"], "permalink_uri": "http://hdl.handle.net/10069/9392", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-11-02"}, "publish_date": "2007-11-02", "publish_status": "0", "recid": "22664", "relation": {}, "relation_version_is_last": true, "title": ["Molecular Targeting Therapy for Renal Cell Carcinoma: Current Status and Our Suggestion"], "weko_shared_id": -1}
Molecular Targeting Therapy for Renal Cell Carcinoma: Current Status and Our Suggestion
http://hdl.handle.net/10069/9392
http://hdl.handle.net/10069/93926eb00673-d651-4b7b-bdf3-038d97f91f36
名前 / ファイル | ライセンス | アクション |
---|---|---|
acta52_02_39.pdf (505.4 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-11-02 | |||||
タイトル | ||||||
タイトル | Molecular Targeting Therapy for Renal Cell Carcinoma: Current Status and Our Suggestion | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Moleculartargettherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Thrombospondin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Matrixmetalloproteinases | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hepatocytegrowthfactorreceptor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Renalcellcarcinoma | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
Miyata, Yasuyoshi
× Miyata, Yasuyoshi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Renal cell carcinoma (RCC) is a common urological malignancy. Patients with low stage RCC have a good prognosis by radical operation. On the other hand, advanced RCC do not respond to most treatment and survival is poor in such patients. Some immuno-therapies were performed to patients with advanced RCC, but the patients who obtained clinically meaningful benefit were very limited. To identify promising targets for novel therapeutic agents, numerous investigations have been carried out regarding the molecular mechanisms of tumor growth and progression. Recently, some molecular-targeting therapies, including anti-vascular endothelial growth factor agent, have demonstrated to prolong survival in phase II and III trials. However, such treatments also showed limited anti-tumoral effects and various severe side effects beyond expectation. These results necessitate more extensive and profound knowledge of pathological features to discuss the treatment strategies for RCC. We have been investigating the molecular mechanism of cancer cell invasion and metastasis in patients with RCC for last few years, and we have obtained several new findings and information about them. In this article, we will describe clinical and pathological significance of several invasion-related and/or angiogenesis-related factors, such as matrix metalloproteinases, thrombospondin, and hepatocyte growth factor/c-Met. These factors are well known to regulate invasive function, angiogenesis, and cancer cell proliferation in various malignant tumors, and animal experiments demonstrated that some selective molecular inhibitors of them could inhibit tumorigenicity and tumor development. Our studies show that some molecular inhibitors may provide a novel therapeutic approach to RCC. | |||||
書誌情報 |
Acta medica Nagasakiensia 巻 52, 号 2, p. 39-43, 発行日 2007-06 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00016055 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508430 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
関係URI | ||||||
関連名称 | http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/52.39 | |||||
sortkey | ||||||
P00039-P00043 | ||||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Acta medica Nagasakiensia. 2007, 52(2), p.39-43 |